BG104451A - Перорални контрацептиви, съдържащи антиестроген ипрогестин - Google Patents

Перорални контрацептиви, съдържащи антиестроген ипрогестин

Info

Publication number
BG104451A
BG104451A BG104451A BG10445100A BG104451A BG 104451 A BG104451 A BG 104451A BG 104451 A BG104451 A BG 104451A BG 10445100 A BG10445100 A BG 10445100A BG 104451 A BG104451 A BG 104451A
Authority
BG
Bulgaria
Prior art keywords
antiestrogen
progestin
peroral
contraceptives
neuterotrophic
Prior art date
Application number
BG104451A
Other languages
English (en)
Inventor
Michael Gast
Christopher Miller
Original Assignee
Wyeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth filed Critical Wyeth
Publication of BG104451A publication Critical patent/BG104451A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретението се отнася до метод за контрацепция,при който на жени в репродуктивна възраст се прилага комбинация от неутеротрофичен антиестроген и прогестин в продължение на 28 дни при 28-дневен менструален цикъл.
BG104451A 1997-11-06 2000-05-17 Перорални контрацептиви, съдържащи антиестроген ипрогестин BG104451A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96508397A 1997-11-06 1997-11-06
PCT/US1998/023427 WO1999024027A2 (en) 1997-11-06 1998-11-04 Anti-estrogen plus progestin containing oral contraceptives

Publications (1)

Publication Number Publication Date
BG104451A true BG104451A (bg) 2000-12-29

Family

ID=25509417

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104451A BG104451A (bg) 1997-11-06 2000-05-17 Перорални контрацептиви, съдържащи антиестроген ипрогестин

Country Status (28)

Country Link
EP (1) EP1051179B1 (bg)
JP (1) JP2001522798A (bg)
CN (1) CN1278732A (bg)
AR (1) AR016667A1 (bg)
AT (1) ATE304359T1 (bg)
AU (2) AU760540B2 (bg)
BG (1) BG104451A (bg)
BR (1) BR9813982A (bg)
CA (1) CA2307210A1 (bg)
CZ (1) CZ294155B6 (bg)
DE (1) DE69831605T2 (bg)
DK (1) DK1051179T3 (bg)
EA (1) EA200000492A1 (bg)
EE (1) EE04092B1 (bg)
ES (1) ES2246541T3 (bg)
GE (1) GEP20043290B (bg)
HR (1) HRP20000269A2 (bg)
HU (1) HUP0100293A3 (bg)
ID (1) ID24568A (bg)
IL (1) IL135621A0 (bg)
NO (1) NO20002167L (bg)
NZ (1) NZ503890A (bg)
PL (1) PL340623A1 (bg)
SK (1) SK6482000A3 (bg)
TR (1) TR200001268T2 (bg)
UA (1) UA68365C2 (bg)
WO (1) WO1999024027A2 (bg)
ZA (1) ZA9810136B (bg)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL120263A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to prevent bone loss-progesterone and estrogen agonists
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
PT1076558E (pt) * 1998-05-15 2003-11-28 Wyeth Corp 2-fenil-1-¬4-(2-aminoetoxi)-benzil|-indole em combinacao com estrogenios
US6380166B1 (en) 1999-09-13 2002-04-30 American Home Products Corporation Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols
JP2003509435A (ja) * 1999-09-13 2003-03-11 ワイス ２−（４−ヒドロキシフェニル）−１−［４−（２−アミン−１−イルエトキシ）ベンジル］−１ｈ−インドール−５−オールのグルコピラノシド複合体
US6376486B1 (en) * 2000-07-06 2002-04-23 American Home Products Corporation Methods of inhibiting sphincter incontinence
PL367094A1 (en) 2001-07-31 2005-02-21 Pfizer Products Inc. Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
PL1809602T3 (pl) 2004-10-27 2009-04-30 Janssen Pharmaceutica Nv Pochodne indolowe przydatne jako modulatory receptora progesteronu
FR2880625B1 (fr) * 2005-01-07 2007-03-09 Sanofi Aventis Sa Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
UY29527A1 (es) * 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
DE102008057230A1 (de) * 2008-11-11 2010-05-12 Bayer Schering Pharma Aktiengesellschaft Synergistische pharmazeutische Kombination mit einem Estrogenrezeptorantagonisten und einem Progestin
PL2580210T3 (pl) 2010-06-10 2017-09-29 Seragon Pharmaceuticals, Inc. Modulatory receptora estrogenowego i ich zastosowania
BR112014014124A2 (pt) 2011-12-14 2017-08-22 Seragon Pharmaceutical Inc Moduladores do receptor de estrogênio fluorados e usos dos mesmos
HUE055321T2 (hu) 2015-10-01 2021-11-29 Olema Pharmaceuticals Inc Tetrahidro-1H-pirido[3,4-b]indol anti-ösztrogén hatóanyagok
US10118910B2 (en) 2015-12-09 2018-11-06 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective estrogen receptor downregulators
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
MX2019000200A (es) 2016-07-01 2019-09-26 G1 Therapeutics Inc Agentes antiproliferativos basados en pirimidina.
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
BR112019013814A2 (pt) 2017-01-06 2020-01-21 G1 Therapeutics Inc método para tratamento de câncer ou de um tumor em um indivíduo, composição farmacêutica, combinação, e, kit.
JP2020507566A (ja) 2017-02-10 2020-03-12 ジー１ セラピューティクス， インコーポレイテッド ベンゾチオフェンエストロゲン受容体モジュレーター
KR102659211B1 (ko) 2017-06-29 2024-04-18 쥐원 쎄라퓨틱스, 인크. G1t38의 형체 형태 및 그의 제조 방법
EP3897631A4 (en) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. TARGETED PROTEIN DEGRADATION
WO2024030968A1 (en) 2022-08-03 2024-02-08 Brystol-Myers Squibb Company Compounds for modulating ret protein
WO2024097980A1 (en) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Ret-ldd protein inhibitors
WO2024097989A1 (en) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Ret-ldd protein degraders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA716118B (en) * 1970-10-05 1972-05-31 Richardson Merrell Inc Contraception
ZA9510926B (en) * 1994-12-23 1996-07-03 Schering Ag Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception
IL120263A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to prevent bone loss-progesterone and estrogen agonists
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
ATE206701T1 (de) * 1996-04-19 2001-10-15 American Home Prod Östrogene verbindungen
US5747480A (en) * 1996-05-08 1998-05-05 American Home Products Corporation Oral contraceptive

Also Published As

Publication number Publication date
HUP0100293A3 (en) 2002-12-28
JP2001522798A (ja) 2001-11-20
NO20002167D0 (no) 2000-04-27
GEP20043290B (en) 2004-07-26
DE69831605T2 (de) 2006-06-14
PL340623A1 (en) 2001-02-12
UA68365C2 (en) 2004-08-16
NZ503890A (en) 2002-08-28
HUP0100293A2 (hu) 2001-10-28
EP1051179B1 (en) 2005-09-14
EE200000211A (et) 2001-04-16
DE69831605D1 (de) 2005-10-20
ES2246541T3 (es) 2006-02-16
EP1051179A2 (en) 2000-11-15
AR016667A1 (es) 2001-07-25
WO1999024027A3 (en) 1999-07-15
ZA9810136B (en) 2000-05-05
CN1278732A (zh) 2001-01-03
CA2307210A1 (en) 1999-05-20
ATE304359T1 (de) 2005-09-15
HRP20000269A2 (en) 2000-12-31
SK6482000A3 (en) 2000-11-07
DK1051179T3 (da) 2005-10-31
CZ294155B6 (cs) 2004-10-13
NO20002167L (no) 2000-06-28
EA200000492A1 (ru) 2000-10-30
IL135621A0 (en) 2001-05-20
EE04092B1 (et) 2003-08-15
AU760540B2 (en) 2003-05-15
AU2003204896B2 (en) 2006-06-15
TR200001268T2 (tr) 2001-01-22
CZ20001661A3 (cs) 2000-12-13
ID24568A (id) 2000-07-27
BR9813982A (pt) 2000-09-26
AU1303199A (en) 1999-05-31
WO1999024027A2 (en) 1999-05-20

Similar Documents

Publication Publication Date Title
BG104451A (bg) Перорални контрацептиви, съдържащи антиестроген ипрогестин
NZ330741A (en) Contraceptive process and kit for female mammals, comprising a combination of gestagen and oestrogen
AU560487B2 (en) Contraceptive comprising gestodene and ethinylestradiol
FI915855A0 (fi) Matalaestrogeenisia oraalisia raskaudenehkäisyvalmisteita
DE69118494D1 (de) Kontrazeptionsverfahren und Schema
BG101553A (bg) Прогестероново-антагонистични и антиестрогенови активни съединения с общо приложение за женски контрацептиви
FI922206A (fi) Osmotisk, oral doseringsform foer fertilitets kontroll.
DE69710896D1 (en) Progestogen-anti-progestogen therapien
LU90341I2 (fr) 75 Ug de désogestrel en l'absence éthinyl oestradiol (cerazette)
NZ333750A (en) Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen
ATE91410T1 (de) Osmotische dosierungsform.
MX9707009A (es) Inyeccion de una vez al mes como un contraceptivo de base y para terapia de reemplazamiento hormonal para mujeres perimenopausicas y premenopausicas.
KR950024496U (ko) 여성용 콘돔(女性用 condom)